GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B7270 CJ 033466Summary: 5-HT4 partial agonist -
B7267 LY 334370 hydrochlorideSummary: 5-HT1F receptor agonist -
B7266 LY 272015 hydrochlorideSummary: 5-HT2B receptor antagonist -
C6665 Higenamine hydrochloride -
B7244 1-MethylpsilocinSummary: 5-HT2C agonist,potent and selective -
C6542 Amitraz -
B7216 Ro 04-6790Summary: 5-HT6 receptor antagonist -
C5822 p-iodo-Clonidine (hydrochloride)Summary: partial agonist of the α2-adrenergic receptor -
B7183 Nefazodone hydrochlorideSummary: 5-HT2A receptor antagonist -
C5802 CarazololSummary: high-affinity, lipophilic, non-selective ligand of the β-adrenergic receptors
